Li C, et al. - Researchers assessed the strength of the link between eight polymorphisms in the excision repair cross complementation (ERCC) genes (rs11615, rs3212986, rs2298881, rs13181, rs1799793, rs1800067, rs2296147, and rs1047768) and prognosis of osteosarcoma patients treated with chemotherapy by analyzing data from relevant studies identified from PubMed, Embase, and Web of Science on human osteosarcoma published prior to July 2017. These studies were focused on overall survival and event-free survival. For data synthesis, STATA software (version 12.0) was utilized. Findings of the analysis of 13 eligible follow-up studies involving 2,303 patients validate the use of rs1799793 and rs2296147 polymorphisms as predictors for prognosis of osteosarcoma patients treated with chemotherapy, as data showed that the survival time might be prolonged by TT genotype in the ERCC2 rs1799793 and ERCC5 rs2296147.